Search Results 1941-1950 of 16383 for Epilepsy (Partial Onset)

1. A Study to Evaluate the Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS - Mayo Clinic

   Disease duration from symptom onset (defined by first muscle weakness or dysarthria) 12-48 months at the time of visit 1 (baseline). Able to perform supine ...

2. A Study to Evaluate the Effectiveness, Safety, and Tolerability of NLY01 in Early-stage Parkinson's Disease - Mayo Clinic

   Participation eligibility · Diagnosis of secondary or atypical parkinsonism. · Onset of any parkinsonian motor sign or symptom > 5 years before Screening Visit.

3. Alisertib in Treating Patients With Advanced or Metastatic Sarcoma - Mayo Clinic

   ... duration of study participation; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration ...

4. A Study to Evaluate Compensatory Training to Support Everyday Function and Adherence to Brain Healthy Lifestyle Changes in Those at Risk for Alzheimer's Disease - Mayo Clinic

   Known neurological disorder with potential cognitive symptoms (a diagnosis of Parkinson's disease, epilepsy, a history of significant TBI, etc.).

5. Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors - Mayo Clinic

   ... duration of study participation, and up to 90 days following completion of therapy: -Total abstinence from sexual intercourse (minimum one complete ...

6. Funding - Mayo Clinic Research

   Mayo Clinic's Neurovascular Research Laboratory receives funding from a variety of sources. Grants. Investigator & Role, Grant Title, Funding Source, Duration ...

7. Neurology Patient Stories - 2011 Archives - Mayo Clinic News Network

   Epilepsy, Brain Surgery and then, Seizure-Free featured image. Epilepsy, Brain Surgery and then, Seizure-Free. Joel Streed. November 2, 2011. Epilepsy Surgery ...

8. lung cancer treatment Archives - Mayo Clinic News Network

   ... seizures for some epilepsy patients. And Dr. Jon Ebbert, an internal medicine and addiction specialist at Mayo Clinic, will discuss alcohol use disorder ...

9. A Study Evaluating the Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma - Mayo Clinic

   History or presence of non-malignant CNS disorder, such as seizure ... duration of 11.18 months versus 5.39 months, respectively. The mean TOX was ...

10. A Study to Compare the Effectiveness and Safety of Emixustat Hydrochloride with Placebo to Treat Macular Atrophy Secondary to Stargadt Disease - Mayo Clinic

    The purpose of this study is to determine if emixustat hydrochloride (emixustat) reduces the rate of progression of macular atrophy (MA) compared to placebo in ...